{"name":"Janssen Cilag S.A.S.","slug":"janssen-cilag-s-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Epo-alpha","genericName":"Epo-alpha","slug":"epo-alpha","indication":"Anemia associated with chronic kidney disease","status":"phase_3"}]}],"pipeline":[{"name":"Epo-alpha","genericName":"Epo-alpha","slug":"epo-alpha","phase":"phase_3","mechanism":"Epo-alpha is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Anemia in cancer patients receiving chemotherapy","Anemia in patients with HIV infection"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFA4dV9FTjNWdEdYdGprckZvdnpiNGFXMm5ZcUF6MGtWdDYwUEhnV3pYZ3VtakE0NElJZkRTZ05NbHVfRXhiM2hYeVU3Sm1QTFp6aDRhLVFPZFc5YnNKTHdOcF9aTV9CSE9M?oc=5","date":"2025-12-30","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNZ1dSV1JKVUgtUmhNd0lCRUllNXZNU1ctVmRXV0VlbTdTS2VOUXNsVjJ3eUpJY3B4MHNRaE1sUG5DRUNhSUhWakEzWTdwdE9xLTNTTXExMkdDd1lYcWVub3BCaE9FZkZwMGtfVmZwaHlMemFrVHJTaHJRSnlibXlPcFdOOVFuR3lkSUdMWEVRU3N3cEp2VVdzYXZiQQ?oc=5","date":"2025-11-18","type":"pipeline","source":"European Medical Journal","summary":"AI-BUS: AI Bowel Ultrasound System - European Medical Journal","headline":"AI-BUS: AI Bowel Ultrasound System","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9TcWZTV1hpdU11dDdrNEN2MVpOejNUdU85cjlfbF9ad2hrUk41REhPanV3T0x3b05CR1pGYWFDcmd5SWNvVlJhWVBUNVF2cDd4eWY0ci1VbTVjelc2RnFv?oc=5","date":"2024-03-07","type":"trial","source":"Nature","summary":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial | Molecular Psychiatry - Natur","headline":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNSmxmaXBIYlFFWHR6QnpmRld6QW4zclZOVkdXNDV2MHRmWGlpcGNNdl9FSWZuaFJza0pDSzQwRmJ3c0h4eDJuU3FValZyaTNzQlpMNzJKMnBYeHJtVGg4TEpEdmJTSVA4ekEyRUJqNVE4RE1QZlphd1Fsd3NMZ3Vaa0hzUGNIcTNkQjk5aklDU1dXRXZUTkNBYkxsSFZsN2hVSWZRbUk2UThNLWw4cEFNRlhLTkNzV3dFZ3VtVC1WYnRIeWdrd1E?oc=5","date":"2020-07-01","type":"pipeline","source":"Cision News","summary":"Photocure appoints Susanne Strauss as Vice President and General Manager of Europe - Cision News","headline":"Photocure appoints Susanne Strauss as Vice President and General Manager of Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQa3BTRU5qajF5MVBOcTRBZDZPanNmTlpOZDRjVVVEMHR4OHRYS0lJZk1pZWxORGgyWDUyX29hWGhXX1BiajVhSXJlUG1kX2NKNFl6aXBsdjd1cXYzZFotQWhmSVhnMkE1YTYyeDdmYWRUUjVhd0dTTHZtUWF2OHhndkFoUEpoOUgzelpaWmwzQVhmWFdFeGZ6WUY3ZGV6UjdlZ0U2MlNHdXh1N0xOUDgwd1FhWktnazNGTnIxOWJGTlVBanV2bHJaU0lMVmhsUWZ2bjYwcmdmUlFaQQ?oc=5","date":"2020-03-18","type":"pipeline","source":"www.hoganlovells.com","summary":"Clawbacks negotiated on the price of pharmaceutical products and pharmaceutical companies’ turnover defined - www.hoganlovells.com","headline":"Clawbacks negotiated on the price of pharmaceutical products and pharmaceutical companies’ turnover defined","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}